APO Research
Talk to an analyst

APO RESEARCH · REPORT

Friedreich Ataxia Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Friedreich Ataxia Drug Industry Research Report 2026

19 December 2025138 pages

Choose your research edition.

Industry ResearchFriedreich Ataxia Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Friedreich Ataxia Drug Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Friedreich Ataxia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Friedreich Ataxia Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Friedreich Ataxia Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Friedreich Ataxia Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Friedreich Ataxia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Friedreich Ataxia Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Friedreich Ataxia Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Friedreich Ataxia Drug include Takeda, Pfizer Inc, Voyager Therapeutics Inc, STATegics Inc, Retrotope Inc, Reata Pharmaceuticals Inc, RaNA Therapeutics Inc, ProQR Therapeutics NV and Ixchel Pharma LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Friedreich Ataxia Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Friedreich Ataxia Drug Market by Company

Takeda

Pfizer Inc

Voyager Therapeutics Inc

STATegics Inc

Retrotope Inc

Reata Pharmaceuticals Inc

RaNA Therapeutics Inc

ProQR Therapeutics NV

Ixchel Pharma LLC

Forward Pharma A/S

Catabasis Pharmaceuticals, Inc.

Cardero Therapeutics Inc

Biovista Inc.

BioMarin Pharmaceutical Inc.

Adverum Biotechnologies Inc

Friedreich Ataxia Drug Segment by Type

BVA-202

BHV-4157

AGIL-FA

ADVM-063

Others

Friedreich Ataxia Drug Segment by Application

Clinic

Hospital

Others

Friedreich Ataxia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Friedreich Ataxia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Friedreich Ataxia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Friedreich Ataxia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Friedreich Ataxia Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Friedreich Ataxia Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Friedreich Ataxia Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Friedreich Ataxia Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Friedreich Ataxia Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Friedreich Ataxia Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Friedreich Ataxia Drug Revenue of Manufacturers (2021-2026) Table 9. Global Friedreich Ataxia Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Friedreich Ataxia Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Friedreich Ataxia Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Friedreich Ataxia Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Friedreich Ataxia Drug, Product Type & Application Table 14. Global Friedreich Ataxia Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Friedreich Ataxia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Takeda Company Information Table 19. Takeda Business Overview Table 20. Takeda Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Takeda Friedreich Ataxia Drug Product Portfolio Table 22. Takeda Recent Developments Table 23. Pfizer Inc Company Information Table 24. Pfizer Inc Business Overview Table 25. Pfizer Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Pfizer Inc Friedreich Ataxia Drug Product Portfolio Table 27. Pfizer Inc Recent Developments Table 28. Voyager Therapeutics Inc Company Information Table 29. Voyager Therapeutics Inc Business Overview Table 30. Voyager Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Voyager Therapeutics Inc Friedreich Ataxia Drug Product Portfolio Table 32. Voyager Therapeutics Inc Recent Developments Table 33. STATegics Inc Company Information Table 34. STATegics Inc Business Overview Table 35. STATegics Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. STATegics Inc Friedreich Ataxia Drug Product Portfolio Table 37. STATegics Inc Recent Developments Table 38. Retrotope Inc Company Information Table 39. Retrotope Inc Business Overview Table 40. Retrotope Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Retrotope Inc Friedreich Ataxia Drug Product Portfolio Table 42. Retrotope Inc Recent Developments Table 43. Reata Pharmaceuticals Inc Company Information Table 44. Reata Pharmaceuticals Inc Business Overview Table 45. Reata Pharmaceuticals Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Reata Pharmaceuticals Inc Friedreich Ataxia Drug Product Portfolio Table 47. Reata Pharmaceuticals Inc Recent Developments Table 48. RaNA Therapeutics Inc Company Information Table 49. RaNA Therapeutics Inc Business Overview Table 50. RaNA Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. RaNA Therapeutics Inc Friedreich Ataxia Drug Product Portfolio Table 52. RaNA Therapeutics Inc Recent Developments Table 53. ProQR Therapeutics NV Company Information Table 54. ProQR Therapeutics NV Business Overview Table 55. ProQR Therapeutics NV Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. ProQR Therapeutics NV Friedreich Ataxia Drug Product Portfolio Table 57. ProQR Therapeutics NV Recent Developments Table 58. Ixchel Pharma LLC Company Information Table 59. Ixchel Pharma LLC Business Overview Table 60. Ixchel Pharma LLC Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Ixchel Pharma LLC Friedreich Ataxia Drug Product Portfolio Table 62. Ixchel Pharma LLC Recent Developments Table 63. Forward Pharma A/S Company Information Table 64. Forward Pharma A/S Business Overview Table 65. Forward Pharma A/S Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Forward Pharma A/S Friedreich Ataxia Drug Product Portfolio Table 67. Forward Pharma A/S Recent Developments Table 68. Catabasis Pharmaceuticals, Inc. Company Information Table 69. Catabasis Pharmaceuticals, Inc. Business Overview Table 70. Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Product Portfolio Table 72. Catabasis Pharmaceuticals, Inc. Recent Developments Table 73. Cardero Therapeutics Inc Company Information Table 74. Cardero Therapeutics Inc Business Overview Table 75. Cardero Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Cardero Therapeutics Inc Friedreich Ataxia Drug Product Portfolio Table 77. Cardero Therapeutics Inc Recent Developments Table 78. Biovista Inc. Company Information Table 79. Biovista Inc. Business Overview Table 80. Biovista Inc. Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Biovista Inc. Friedreich Ataxia Drug Product Portfolio Table 82. Biovista Inc. Recent Developments Table 83. BioMarin Pharmaceutical Inc. Company Information Table 84. BioMarin Pharmaceutical Inc. Business Overview Table 85. BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Product Portfolio Table 87. BioMarin Pharmaceutical Inc. Recent Developments Table 88. Adverum Biotechnologies Inc Company Information Table 89. Adverum Biotechnologies Inc Business Overview Table 90. Adverum Biotechnologies Inc Friedreich Ataxia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Adverum Biotechnologies Inc Friedreich Ataxia Drug Product Portfolio Table 92. Adverum Biotechnologies Inc Recent Developments Table 93. Global Friedreich Ataxia Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Friedreich Ataxia Drug Sales by Region (2021-2026) & (K Units) Table 95. Global Friedreich Ataxia Drug Sales Market Share by Region (2021-2026) Table 96. Global Friedreich Ataxia Drug Sales by Region (2027-2032) & (K Units) Table 97. Global Friedreich Ataxia Drug Sales Market Share by Region (2027-2032) Table 98. Global Friedreich Ataxia Drug Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Friedreich Ataxia Drug Revenue Market Share by Region (2021-2026) Table 100. Global Friedreich Ataxia Drug Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Friedreich Ataxia Drug Revenue Market Share by Region (2027-2032) Table 102. North America Friedreich Ataxia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Friedreich Ataxia Drug Sales by Country (2021-2026) & (K Units) Table 104. North America Friedreich Ataxia Drug Sales by Country (2027-2032) & (K Units) Table 105. North America Friedreich Ataxia Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Friedreich Ataxia Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Friedreich Ataxia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Friedreich Ataxia Drug Sales by Country (2021-2026) & (K Units) Table 109. Europe Friedreich Ataxia Drug Sales by Country (2027-2032) & (K Units) Table 110. Europe Friedreich Ataxia Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Friedreich Ataxia Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Friedreich Ataxia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Friedreich Ataxia Drug Sales by Country (2021-2026) & (K Units) Table 114. Asia Pacific Friedreich Ataxia Drug Sales by Country (2027-2032) & (K Units) Table 115. Asia Pacific Friedreich Ataxia Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Friedreich Ataxia Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Friedreich Ataxia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Friedreich Ataxia Drug Sales by Country (2021-2026) & (K Units) Table 119. South America Friedreich Ataxia Drug Sales by Country (2027-2032) & (K Units) Table 120. South America Friedreich Ataxia Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Friedreich Ataxia Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Friedreich Ataxia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Friedreich Ataxia Drug Sales by Country (2021-2026) & (K Units) Table 124. Middle East and Africa Friedreich Ataxia Drug Sales by Country (2027-2032) & (K Units) Table 125. Middle East and Africa Friedreich Ataxia Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Friedreich Ataxia Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Friedreich Ataxia Drug Sales by Type (2021-2026) & (K Units) Table 128. Global Friedreich Ataxia Drug Sales by Type (2027-2032) & (K Units) Table 129. Global Friedreich Ataxia Drug Sales Market Share by Type (2021-2026) Table 130. Global Friedreich Ataxia Drug Sales Market Share by Type (2027-2032) Table 131. Global Friedreich Ataxia Drug Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Friedreich Ataxia Drug Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Friedreich Ataxia Drug Revenue Market Share by Type (2021-2026) Table 134. Global Friedreich Ataxia Drug Revenue Market Share by Type (2027-2032) Table 135. Global Friedreich Ataxia Drug Price by Type (2021-2026) & (US$/Unit) Table 136. Global Friedreich Ataxia Drug Price by Type (2027-2032) & (US$/Unit) Table 137. Global Friedreich Ataxia Drug Sales by Application (2021-2026) & (K Units) Table 138. Global Friedreich Ataxia Drug Sales by Application (2027-2032) & (K Units) Table 139. Global Friedreich Ataxia Drug Sales Market Share by Application (2021-2026) Table 140. Global Friedreich Ataxia Drug Sales Market Share by Application (2027-2032) Table 141. Global Friedreich Ataxia Drug Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Friedreich Ataxia Drug Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Friedreich Ataxia Drug Revenue Market Share by Application (2021-2026) Table 144. Global Friedreich Ataxia Drug Revenue Market Share by Application (2027-2032) Table 145. Global Friedreich Ataxia Drug Price by Application (2021-2026) & (US$/Unit) Table 146. Global Friedreich Ataxia Drug Price by Application (2027-2032) & (US$/Unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Friedreich Ataxia Drug Distributors List Table 150. Friedreich Ataxia Drug Customers List Table 151. Friedreich Ataxia Drug Industry Trends Table 152. Friedreich Ataxia Drug Industry Drivers Table 153. Friedreich Ataxia Drug Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Friedreich Ataxia Drug Product Image Figure 5. Global Friedreich Ataxia Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Friedreich Ataxia Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Friedreich Ataxia Drug Sales (2021-2032) & (K Units) Figure 8. Global Friedreich Ataxia Drug Average Price (US$/Unit) & (2021-2032) Figure 9. BVA-202 Product Image Figure 10. BHV-4157 Product Image Figure 11. AGIL-FA Product Image Figure 12. ADVM-063 Product Image Figure 13. Others Product Image Figure 14. Clinic Product Image Figure 15. Hospital Product Image Figure 16. Others Product Image Figure 17. Global Friedreich Ataxia Drug Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Friedreich Ataxia Drug, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Friedreich Ataxia Drug Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Friedreich Ataxia Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Friedreich Ataxia Drug Sales by Region in 2025 Figure 23. Global Friedreich Ataxia Drug Revenue by Region in 2025 Figure 24. North America Friedreich Ataxia Drug Market Size by Country in 2025 Figure 25. North America Friedreich Ataxia Drug Sales Market Share by Country (2021-2032) Figure 26. North America Friedreich Ataxia Drug Revenue Market Share by Country (2021-2032) Figure 27. United States Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Friedreich Ataxia Drug Market Size by Country in 2025 Figure 30. Europe Friedreich Ataxia Drug Sales Market Share by Country (2021-2032) Figure 31. Europe Friedreich Ataxia Drug Revenue Market Share by Country (2021-2032) Figure 32. Germany Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Asia Pacific Friedreich Ataxia Drug Market Size by Country in 2025 Figure 38. Asia Pacific Friedreich Ataxia Drug Sales Market Share by Country (2021-2032) Figure 39. Asia Pacific Friedreich Ataxia Drug Revenue Market Share by Country (2021-2032) Figure 40. China Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Japan Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. South Korea Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. India Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Australia Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. China Taiwan Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South America Friedreich Ataxia Drug Market Size by Country in 2025 Figure 49. South America Friedreich Ataxia Drug Sales Market Share by Country (2021-2032) Figure 50. South America Friedreich Ataxia Drug Revenue Market Share by Country (2021-2032) Figure 51. Mexico Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Brazil Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Argentina Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Middle East and Africa Friedreich Ataxia Drug Market Size by Country in 2025 Figure 55. Middle East and Africa Friedreich Ataxia Drug Sales Market Share by Country (2021-2032) Figure 56. Middle East and Africa Friedreich Ataxia Drug Revenue Market Share by Country (2021-2032) Figure 57. Turkey Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. UAE Friedreich Ataxia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Global Friedreich Ataxia Drug Sales Market Share by Type (2021-2032) Figure 61. Global Friedreich Ataxia Drug Revenue Market Share by Type (2021-2032) Figure 62. Global Friedreich Ataxia Drug Price (US$/Unit) by Type (2021-2032) Figure 63. Global Friedreich Ataxia Drug Sales Market Share by Application (2021-2032) Figure 64. Global Friedreich Ataxia Drug Revenue Market Share by Application (2021-2032) Figure 65. Global Friedreich Ataxia Drug Price (US$/Unit) by Application (2021-2032) Figure 66. Friedreich Ataxia Drug Value Chain Figure 67. Friedreich Ataxia Drug Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Friedreich Ataxia Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • BVA-202
  • BHV-4157
  • AGIL-FA
  • ADVM-063
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Takeda
  • Pfizer Inc
  • Voyager Therapeutics Inc
  • STATegics Inc
  • Retrotope Inc
  • Reata Pharmaceuticals Inc
  • RaNA Therapeutics Inc
  • ProQR Therapeutics NV
  • Ixchel Pharma LLC
  • Forward Pharma A/S
  • Catabasis Pharmaceuticals, Inc.
  • Cardero Therapeutics Inc
  • Biovista Inc.
  • BioMarin Pharmaceutical Inc.
  • Adverum Biotechnologies Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Friedreich Ataxia Drug Market Size (2021-2032)
  4. 2.2.2 Global Friedreich Ataxia Drug Sales (2021-2032)
  5. 2.2.3 Global Friedreich Ataxia Drug Market Average Price (2021-2032)
  6. 2.3 Friedreich Ataxia Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 BVA-202
  9. 2.3.3 BHV-4157
  10. 2.3.4 AGIL-FA
  11. 2.3.5 ADVM-063
  12. 2.3.6 Others
  13. 2.4 Friedreich Ataxia Drug by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Clinic
  16. 2.4.3 Hospital
  17. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Friedreich Ataxia Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Friedreich Ataxia Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Friedreich Ataxia Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Friedreich Ataxia Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Friedreich Ataxia Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Friedreich Ataxia Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Friedreich Ataxia Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Friedreich Ataxia Drug, Established Date
  9. 3.9 Global Friedreich Ataxia Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Takeda
  2. 4.1.1 Takeda Company Information
  3. 4.1.2 Takeda Business Overview
  4. 4.1.3 Takeda Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Takeda Friedreich Ataxia Drug Product Portfolio
  6. 4.1.5 Takeda Recent Developments
  7. 4.2 Pfizer Inc
  8. 4.2.1 Pfizer Inc Company Information
  9. 4.2.2 Pfizer Inc Business Overview
  10. 4.2.3 Pfizer Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Pfizer Inc Friedreich Ataxia Drug Product Portfolio
  12. 4.2.5 Pfizer Inc Recent Developments
  13. 4.3 Voyager Therapeutics Inc
  14. 4.3.1 Voyager Therapeutics Inc Company Information
  15. 4.3.2 Voyager Therapeutics Inc Business Overview
  16. 4.3.3 Voyager Therapeutics Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Voyager Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
  18. 4.3.5 Voyager Therapeutics Inc Recent Developments
  19. 4.4 STATegics Inc
  20. 4.4.1 STATegics Inc Company Information
  21. 4.4.2 STATegics Inc Business Overview
  22. 4.4.3 STATegics Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 STATegics Inc Friedreich Ataxia Drug Product Portfolio
  24. 4.4.5 STATegics Inc Recent Developments
  25. 4.5 Retrotope Inc
  26. 4.5.1 Retrotope Inc Company Information
  27. 4.5.2 Retrotope Inc Business Overview
  28. 4.5.3 Retrotope Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Retrotope Inc Friedreich Ataxia Drug Product Portfolio
  30. 4.5.5 Retrotope Inc Recent Developments
  31. 4.6 Reata Pharmaceuticals Inc
  32. 4.6.1 Reata Pharmaceuticals Inc Company Information
  33. 4.6.2 Reata Pharmaceuticals Inc Business Overview
  34. 4.6.3 Reata Pharmaceuticals Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Reata Pharmaceuticals Inc Friedreich Ataxia Drug Product Portfolio
  36. 4.6.5 Reata Pharmaceuticals Inc Recent Developments
  37. 4.7 RaNA Therapeutics Inc
  38. 4.7.1 RaNA Therapeutics Inc Company Information
  39. 4.7.2 RaNA Therapeutics Inc Business Overview
  40. 4.7.3 RaNA Therapeutics Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 RaNA Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
  42. 4.7.5 RaNA Therapeutics Inc Recent Developments
  43. 4.8 ProQR Therapeutics NV
  44. 4.8.1 ProQR Therapeutics NV Company Information
  45. 4.8.2 ProQR Therapeutics NV Business Overview
  46. 4.8.3 ProQR Therapeutics NV Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 ProQR Therapeutics NV Friedreich Ataxia Drug Product Portfolio
  48. 4.8.5 ProQR Therapeutics NV Recent Developments
  49. 4.9 Ixchel Pharma LLC
  50. 4.9.1 Ixchel Pharma LLC Company Information
  51. 4.9.2 Ixchel Pharma LLC Business Overview
  52. 4.9.3 Ixchel Pharma LLC Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Ixchel Pharma LLC Friedreich Ataxia Drug Product Portfolio
  54. 4.9.5 Ixchel Pharma LLC Recent Developments
  55. 4.10 Forward Pharma A/S
  56. 4.10.1 Forward Pharma A/S Company Information
  57. 4.10.2 Forward Pharma A/S Business Overview
  58. 4.10.3 Forward Pharma A/S Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Forward Pharma A/S Friedreich Ataxia Drug Product Portfolio
  60. 4.10.5 Forward Pharma A/S Recent Developments
  61. 4.11 Catabasis Pharmaceuticals, Inc.
  62. 4.11.1 Catabasis Pharmaceuticals, Inc. Company Information
  63. 4.11.2 Catabasis Pharmaceuticals, Inc. Business Overview
  64. 4.11.3 Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Product Portfolio
  66. 4.11.5 Catabasis Pharmaceuticals, Inc. Recent Developments
  67. 4.12 Cardero Therapeutics Inc
  68. 4.12.1 Cardero Therapeutics Inc Company Information
  69. 4.12.2 Cardero Therapeutics Inc Business Overview
  70. 4.12.3 Cardero Therapeutics Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Cardero Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
  72. 4.12.5 Cardero Therapeutics Inc Recent Developments
  73. 4.13 Biovista Inc.
  74. 4.13.1 Biovista Inc. Company Information
  75. 4.13.2 Biovista Inc. Business Overview
  76. 4.13.3 Biovista Inc. Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Biovista Inc. Friedreich Ataxia Drug Product Portfolio
  78. 4.13.5 Biovista Inc. Recent Developments
  79. 4.14 BioMarin Pharmaceutical Inc.
  80. 4.14.1 BioMarin Pharmaceutical Inc. Company Information
  81. 4.14.2 BioMarin Pharmaceutical Inc. Business Overview
  82. 4.14.3 BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Product Portfolio
  84. 4.14.5 BioMarin Pharmaceutical Inc. Recent Developments
  85. 4.15 Adverum Biotechnologies Inc
  86. 4.15.1 Adverum Biotechnologies Inc Company Information
  87. 4.15.2 Adverum Biotechnologies Inc Business Overview
  88. 4.15.3 Adverum Biotechnologies Inc Friedreich Ataxia Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Adverum Biotechnologies Inc Friedreich Ataxia Drug Product Portfolio
  90. 4.15.5 Adverum Biotechnologies Inc Recent Developments
5 Global Friedreich Ataxia Drug Market Scenario by Region
  1. 5.1 Global Friedreich Ataxia Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Friedreich Ataxia Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Friedreich Ataxia Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Friedreich Ataxia Drug Sales by Region: 2027-2032
  5. 5.3 Global Friedreich Ataxia Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Friedreich Ataxia Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Friedreich Ataxia Drug Revenue by Region: 2027-2032
  8. 5.4 North America Friedreich Ataxia Drug Market Facts & Figures by Country
  9. 5.4.1 North America Friedreich Ataxia Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Friedreich Ataxia Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Friedreich Ataxia Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Friedreich Ataxia Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Friedreich Ataxia Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Friedreich Ataxia Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Friedreich Ataxia Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Friedreich Ataxia Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Friedreich Ataxia Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Friedreich Ataxia Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Friedreich Ataxia Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Friedreich Ataxia Drug Market Facts & Figures by Country
  35. 5.7.1 South America Friedreich Ataxia Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Friedreich Ataxia Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Friedreich Ataxia Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Friedreich Ataxia Drug Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Friedreich Ataxia Drug Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Friedreich Ataxia Drug Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Friedreich Ataxia Drug Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Friedreich Ataxia Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Friedreich Ataxia Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Friedreich Ataxia Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Friedreich Ataxia Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Friedreich Ataxia Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Friedreich Ataxia Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Friedreich Ataxia Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Friedreich Ataxia Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Friedreich Ataxia Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Friedreich Ataxia Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Friedreich Ataxia Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Friedreich Ataxia Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Friedreich Ataxia Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Friedreich Ataxia Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Friedreich Ataxia Drug Value Chain Analysis
  2. 8.1.1 Friedreich Ataxia Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Friedreich Ataxia Drug Production Mode & Process
  5. 8.2 Friedreich Ataxia Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Friedreich Ataxia Drug Distributors
  8. 8.2.3 Friedreich Ataxia Drug Customers
9 Global Friedreich Ataxia Drug Analyzing Market Dynamics
  1. 9.1 Friedreich Ataxia Drug Industry Trends
  2. 9.2 Friedreich Ataxia Drug Industry Drivers
  3. 9.3 Friedreich Ataxia Drug Industry Opportunities and Challenges
  4. 9.4 Friedreich Ataxia Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst